Category Archives: Global News Feed

– Quarter-end cash position of $105.7 million provides ample cash runway into mid-2024 –

Go here to read the rest:
Rain Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics

Read more from the original source:
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell) (Nasdaq: LYEL), a clinical?stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today provided business highlights and reported financial results for the second quarter of 2022.

Excerpt from:
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights

WALTHAM Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to two new employees with a grant date of August 1, 2022, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Continued here:
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

- Recently-announced company restructuring focuses internal efforts on wholly-owned next-generation conditionally activated therapeutics, extending cash runway to 2025 -

View original post here:
CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Cash balance of $312.2M expected to fund operations into 2025 Cash balance of $312.2M expected to fund operations into 2025

See the original post here:
Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2022 and provided business updates.

See the original post here:
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

The rest is here:
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

Reported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline results for full pivotal study population expected in the first quarter of 2023

Read the original here:
Day One Reports Second Quarter 2022 Financial Results and Corporate Progress

Company expects to report results of preclinical MPS-1 studies in second half of 2022 to inform pipeline strategy Company expects to report results of preclinical MPS-1 studies in second half of 2022 to inform pipeline strategy

Excerpt from:
Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights